530 related articles for article (PubMed ID: 17401012)
1. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.
Loi S; Haibe-Kains B; Desmedt C; Lallemand F; Tutt AM; Gillet C; Ellis P; Harris A; Bergh J; Foekens JA; Klijn JG; Larsimont D; Buyse M; Bontempi G; Delorenzi M; Piccart MJ; Sotiriou C
J Clin Oncol; 2007 Apr; 25(10):1239-46. PubMed ID: 17401012
[TBL] [Abstract][Full Text] [Related]
2. Challenges in projecting clustering results across gene expression-profiling datasets.
Lusa L; McShane LM; Reid JF; De Cecco L; Ambrogi F; Biganzoli E; Gariboldi M; Pierotti MA
J Natl Cancer Inst; 2007 Nov; 99(22):1715-23. PubMed ID: 18000217
[TBL] [Abstract][Full Text] [Related]
3. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers.
Oh DS; Troester MA; Usary J; Hu Z; He X; Fan C; Wu J; Carey LA; Perou CM
J Clin Oncol; 2006 Apr; 24(11):1656-64. PubMed ID: 16505416
[TBL] [Abstract][Full Text] [Related]
4. The genomic profile of HER2-amplified breast cancers: the influence of ER status.
Marchiò C; Natrajan R; Shiu KK; Lambros MB; Rodriguez-Pinilla SM; Tan DS; Lord CJ; Hungermann D; Fenwick K; Tamber N; Mackay A; Palacios J; Sapino A; Buerger H; Ashworth A; Reis-Filho JS
J Pathol; 2008 Dec; 216(4):399-407. PubMed ID: 18810758
[TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of hormone receptor positive (luminal) breast cancers: what have we learnt?
Loi S
Eur J Cancer; 2008 Dec; 44(18):2813-8. PubMed ID: 18990560
[TBL] [Abstract][Full Text] [Related]
6. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
7. [Gene expression profiling of ER+ breast cancers: to discriminate the poor prognosis tumors or to define the most suitable treatment?].
Chanrion M; Darbon JM
Bull Cancer; 2008 May; 95(5):513-8. PubMed ID: 18541515
[TBL] [Abstract][Full Text] [Related]
8. Understanding the molecular basis of histologic grade.
Ignatiadis M; Sotiriou C
Pathobiology; 2008; 75(2):104-11. PubMed ID: 18544965
[TBL] [Abstract][Full Text] [Related]
9. GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value.
Voduc D; Cheang M; Nielsen T
Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):365-73. PubMed ID: 18268121
[TBL] [Abstract][Full Text] [Related]
10. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
[TBL] [Abstract][Full Text] [Related]
11. A modular analysis of breast cancer reveals a novel low-grade molecular signature in estrogen receptor-positive tumors.
Yu K; Ganesan K; Miller LD; Tan P
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3288-96. PubMed ID: 16740749
[TBL] [Abstract][Full Text] [Related]
12. Predicting features of breast cancer with gene expression patterns.
Lu X; Lu X; Wang ZC; Iglehart JD; Zhang X; Richardson AL
Breast Cancer Res Treat; 2008 Mar; 108(2):191-201. PubMed ID: 18297396
[TBL] [Abstract][Full Text] [Related]
13. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
14. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
15. Concordance among gene-expression-based predictors for breast cancer.
Fan C; Oh DS; Wessels L; Weigelt B; Nuyten DS; Nobel AB; van't Veer LJ; Perou CM
N Engl J Med; 2006 Aug; 355(6):560-9. PubMed ID: 16899776
[TBL] [Abstract][Full Text] [Related]
16. Molecular classification of estrogen receptor-positive/luminal breast cancers.
Geyer FC; Rodrigues DN; Weigelt B; Reis-Filho JS
Adv Anat Pathol; 2012 Jan; 19(1):39-53. PubMed ID: 22156833
[TBL] [Abstract][Full Text] [Related]
17. Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast.
Vincent-Salomon A; Lucchesi C; Gruel N; Raynal V; Pierron G; Goudefroye R; Reyal F; Radvanyi F; Salmon R; Thiery JP; Sastre-Garau X; Sigal-Zafrani B; Fourquet A; Delattre O;
Clin Cancer Res; 2008 Apr; 14(7):1956-65. PubMed ID: 18381933
[TBL] [Abstract][Full Text] [Related]
18. Gene-expression analysis and the basal-like breast cancer subtype.
Finnegan TJ; Carey LA
Future Oncol; 2007 Feb; 3(1):55-63. PubMed ID: 17280502
[TBL] [Abstract][Full Text] [Related]
19. Clinical validation of a customized multiple signature microarray for breast cancer.
Tan BK; Tan LK; Yu K; Tan PH; Lee M; Sii LH; Wong CY; Ho GH; Yeo AW; Chow PK; Koong HN; Yong WS; Lim DT; Ooi LL; Soo KC; Tan P
Clin Cancer Res; 2008 Jan; 14(2):461-9. PubMed ID: 18223220
[TBL] [Abstract][Full Text] [Related]
20. Cytokeratin KRT8/18 expression differentiates distinct subtypes of grade 3 invasive ductal carcinoma of the breast.
Walker LC; Harris GC; Holloway AJ; McKenzie GW; Wells JE; Robinson BA; Morris CM
Cancer Genet Cytogenet; 2007 Oct; 178(2):94-103. PubMed ID: 17954264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
